CD25, the alpha subunit of the IL2 receptor, is a canonical marker of regulatory T cells (Treg) and hence has been implicated in immune suppression in cancer. However, CD25 is also required for optimal expansion and activity of effector T cells in peripheral tissues. Thus, we hypothesized that CD25, in addition to demarcating Tregs, might identify effector T cells in cancer. To investigate this possibility, we used multiparameter flow cytometry and IHC to analyze tumor-infiltrating lymphocytes (TIL) in primary high-grade serous carcinomas, the most common and fatal subtype of ovarian cancer. CD25 was expressed primarily by CD4 þ TIL, with negligible expression by CD8 þ TIL.
Introduction
Studies over the past decade have highlighted the strong influence of the immune system on the survival of patients with cancer. In particular, CD8 þ tumor-infiltrating lymphocytes (CD8 þ TIL) are associated with improved survival in virtually every human solid cancer studied, including ovarian cancer (1, 2) . Importantly, however, CD8 þ TIL do not act in isolation but rather through cooperative interactions with other immune cells (3) . Thus, to enhance the beneficial effects of TIL, it is imperative to understand how different TIL subsets work together to mediate tumor immunity. Gooden and colleagues (4) performed a meta-analysis of 52 studies investigating the prognostic significance of TIL expressing the T-cell markers CD3, CD8, CD4, and FoxP3. Intriguingly, CD3
þ TIL showed a stronger prognostic effect than CD8 þ TIL (pooled HRs of 0.58 and 0.71, respectively), suggesting that other CD3 þ TIL, in particular CD4 þ T cells, might contribute to the favorable prognosis. The prognostic influence of CD4 þ TIL has been difficult to assess directly as they include both effector and regulatory subsets (5) . Furthermore, CD4 is also expressed by macrophages in humans, thus complicating the histopathologic scoring (6) . Owing to this complexity, CD4 as a standalone marker has shown no association with patient survival in ovarian cancer (7, 8) . CD4 þ TIL have been divided into several distinct functional subsets based on cytokine secretion patterns and phenotypic markers (5) . For example, IFNg-producing CD4 þ TIL (Th1 cells) have been identified in ovarian cancer (9) , and Th1-like gene expression signatures have been reported as prognostically favorable in many cancers (1) . More recently, IL17-producing CD4 þ T cells (Th17 cells) have been identified in several cancers (1) . The prognostic effect of Th17 cells appears to depend on tumor site, ranging from unfavorable in colorectal cancer (10) to favorable in ovarian and gastric cancer (11, 12) . CD4 þ TIL with a regulatory phenotype (Treg) are also prevalent in human cancers. Regulatory T cells (Treg) are commonly defined by coexpression of the IL2 receptor (IL2R) alpha subunit (CD25) and the transcription factor FoxP3. These cells can inhibit tumor immunity by a variety of mechanisms, including the production of immunosuppressive cytokines, depletion of extracellular ATP, and inhibitory cell contacts (13) . Accordingly, Tregs have been associated with poor prognosis in ovarian cancer (8, (14) (15) (16) and many other cancer types (1, 17) . Thus, CD4
þ TIL represent complex mixtures of T-cell subsets with both positive and negative influences on tumor immunity. Although IL2 can serve as a growth factor for virtually all T-cell subsets, Tregs exhibit the most obvious IL2 dependency in vivo.
This was revealed most strikingly when IL2-and IL2R-deficient mice were first generated. Rather than being immune compromised as many had expected, these animals develop a lethal, systemic autoimmune syndrome that is attributable to the loss of Tregs (18) . Thus, CD25 serves not only as a marker of Tregs but also as a component of an essential developmental and homeostatic signaling pathway for these cells (18) . Accordingly, several strategies have been developed to deplete Tregs in patients with cancer by targeting the IL2 pathway. For example, IL2 conjugated to diphtheria toxin has been used to deplete Tregs in vivo (19, 20) . Tregs can also be depleted with antibodies to CD25 (21) . Although these agents have been shown to reduce the number of circulating Tregs in patients with cancer, and improve responses to tumor-specific vaccines, this has generally not resulted in major antitumor effects. Indeed, in the settings of transplantation and autoimmunity, these agents have proven efficacious at inhibiting T-cell responses rather than reversing immune suppression (22) .
Consistent with this, a closer examination of IL2-or CD25-deficient mice has revealed an important role for IL2 in the expansion of effector T cells in nonlymphoid tissues such as gut and lung epithelium (23, 24) . Moreover, we found in a mouse model of advanced ovarian cancer that IL2 signaling, though dispensable for the initial expansion of CD8 þ T cells, was essential for CD8 þ T-cell responses in the tumor environment (25) . Indeed, systemic IL2 infusion can have potent antitumor effects as a monotherapy and in the setting of adoptive immunotherapy (26) . In ovarian cancer, intraperitoneal IL2 administration yielded a 25% objective response rate in early-phase clinical trials (27, 28) . Thus, the physiologic role of IL2 is highly contextdependent, and a better understanding of its role in the tumor microenvironment is needed if we are to rationally manipulate this signaling axis. Toward this end, we evaluated the phenotype and prognostic significance of CD25 þ TIL subsets in high-grade serous carcinoma (HGSC), the most common and lethal form of ovarian cancer. In accord with prior reports (8, (14) (15) (16) 
Materials and Methods

Patient characteristics and biospecimens
All specimens and clinical data were obtained with either written informed consent or a formal waiver of consent under protocols approved by the Research Ethics Board of the British Columbia Cancer Agency (BCCA) and the University of British Columbia (Vancouver, British Columbia, Canada). All patients in this study were diagnosed with advanced stage HGSC. Survival analyses were performed with a previously described retrospective cohort comprised of 187 HGSC cases (Table 1; refs. 7, 29) . Briefly, a tissue microarray (TMA) with 0.6-mm cores was constructed from formalin-fixed paraffin-embedded tumor samples obtained at the time of primary surgery from patients seen at the BC Cancer Agency from 1984 to 2000 (OvCaRe Ovarian Tumour Bank).
Patients in this cohort were deemed optimally de-bulked, meaning they had no macroscopic residual disease.
Flow cytometry studies were performed with viable tumor and blood specimens collected at the time of primary surgery from previously untreated patients with HGSC admitted to BCCA from 2007 to 2010. Tumor tissue samples were mechanically disaggregated in RPMI media containing 0.5 mg/mL collagenase Type I (Sigma-Aldrich), 0.5 mg/mL collagenase Type IV (Sigma-Aldrich), 0.25 mg/mL hyaluronidase (Sigma-Aldrich), and 0.1 mg/mL DNAse I (Sigma-Aldrich) and incubated for 12 hours at 4
C. Single-cell suspensions were prepared by passing digested tissue through a 100-mm filter. Cellular yield and viability were determined by flow cytometry, and aliquots of 1 Â 10 7 cells were frozen in RPMI media containing 50% FBS (Fisher Scientific) and 10% DMSO (Sigma-Aldrich).
Flow cytometry
Tumor-cell suspensions were thawed at 37 C followed by washing and a 2-hour rest at 37 C in RPMI media (Life Technologies) containing 10% FBS (Fisher Scientific), L-glutamine (Life Technologies), sodium pyruvate (Life Technologies), b-mercaptoethanol (Sigma-Aldrich), and HEPES (Life Technologies). Cells were stained with fluorochrome-conjugated monoclonal antibodies to the following cell surface markers: CCR4, CCR6, CD3, CD4, CD8, CD25, CD127, CD357 (GITR), CTLA-4, CXCR3, CXCR5, LAG-3, OX40, PD-1, and TIM-3 (Supplementary Table  S1 ). To analyze cytokine production, bulk tumor preparations were stimulated with phorbol myristate acetate (PMA; 50 ng/mL; Sigma-Aldrich) and ionomycin (1 mmol/L; Sigma-Aldrich) in the presence of GolgiStop (BD Biosciences) for 3 hours at 37 C. Cells were then fixed and permeabilized with Perm/Fix solution (eBiosciences) and stained with fluorochrome-conjugated monoclonal antibodies to IFNg, TNFa, IL2, IL4, and IL17 (Supplementary Table S1 ). Analysis of FoxP3 and Helios was performed simultaneously with intracellular cytokine staining. For analysis of T-bet, GATA-3, and RORgt, unstimulated bulk tumor preparations were stained using the Transcription Factor Buffer Set (BD Biosciences) according to the manufacturer's protocol. To generate positive controls for T-bet and GATA-3 staining, Th1 and Th2 lines were produced by stimulating healthy donor peripheral blood mononuclear cells (PBMC) for 5 days with anti-CD3 and anti-CD28 in the presence of IL2 (30 U/mL) þ IL12 (20 ng/mL) or IL4 (10 mg/ mL), respectively. Flow cytometry was performed using eightchannel Influx or FACSCalibur instruments (BD Biosciences), and data were analyzed with FlowJo software v10.0.7 (TreeStar Inc.).
IHC
Multicolor IHC was performed as previously described (30) . Briefly, TMAs were stained with pan-cytokeratin alone or the following antibody combinations: (i) CD25, CD8, and FoxP3 and (ii) CD3, CD8, and FoxP3 (Supplementary Table S1 ). All slides were deparaffinized, treated with Diva Decloaker in a Decloaking Chamber for antigen retrieval, and then blocked with Peroxidased-1 and Background Sniper. All staining was performed at room temperature for one hour for the primary antibodies and 30 minutes for secondary amplification. For the pancytokeratin stain, the primary signal was amplified using the MACH-2 Mouse-AP polymer Kit and visualized with Warp Red (10 minutes). The first antibody combination utilized anti-CD25 (clone 4C9) and anti-CD8a (clone SP16) antibodies, the MACH-2 polymer kit Double Stain 1, and the chromogens Warp Red and Betazoid DAB, respectively. Slides were denatured at 50 C for 45 minutes to remove the primary and secondary antibodies (31) . The anti-CD25 antibody (clone 4C9) was reapplied (to boost the signal) together with the anti-FoxP3 antibody (clone SP97), followed by the secondary polymer Kit MACH-2 Double Stain 1 and development with Warp Red and Vina Green, respectively. For the second antibody combination, we used the primary antibodies anti-CD3 (clone SP7) and anti-CD8a (clone C8/ 144B), the secondary polymer kit MACH-2 Double stain 2, and Warp Red and Betazoid DAB, respectively. After denaturation, the second round of staining used anti-FoxP3 antibody (clone SP97), the secondary polymer MACH-2 Double Stain 2, and Vina Green. Where indicated, slides were counterstained with hematoxylin. Other than antibodies (Supplementary Table S1 ), all IHC reagents and equipment were obtained from Biocare Medical.
Image analysis and scoring
Images were captured using an Olympus BX53 microscope equipped with a motorized stage (Quorum Technologies Inc.) and the Nuance multispectral imaging system (CRI). Pan-cytokeratin-stained TMA cores were captured as a single image at 200Â magnification. For cores stained with the CD8/CD25/ FoxP3 and CD3/CD8/FoxP3 combinations, each chromogen was scanned at its optimal wavelength and 400Â magnification. Images were then combined electronically using MetaMorph software (Quorum Technologies Inc.). To aid the identification of intraepithelial TIL (as opposed to stromal lymphocytes), cytokeratin-positive tumor regions were overlaid on serial sections stained for TIL markers ( Supplementary Fig. S1 ). To enumerate TIL, multispectral images were deconvoluted into individual components using Nuance software. Using Metamorph software (Quorum Technologies Inc.), images containing three chromogens were re-created and used to visually count cells with the indicated phenotypes.
Cases were considered positive for a given TIL subset if at least one cell was present per 0.6-mm core. The density of each intraepithelial TIL subset was calculated by normalizing cell counts by epithelial area as defined by positive cytokeratin staining on a neighboring tissue section. The mean number of CD25 À FoxP3 À TIL was inferred for the cohort by subtracting the mean number of CD8 
Statistical analysis
All statistical analyses were performed using GraphPad Prism 6.0. Survival analysis was performed using Kaplan-Meier plots and log-rank tests. Pearson correlations were used to assess associations between TIL subsets. The c 2 analysis was used to assess the association of TIL subsets with MHC class II. P values of less than 0.05 were considered statistically significant.
Results
CD25 and FoxP3 define four subsets of CD4
þ TIL
To assess which populations of TIL express CD25, we performed multiparameter flow cytometry on disaggregated tumor samples from 12 patients with HGSC. CD25 was expressed by a small but significant proportion of CD3 þ TIL (mean, 12%; range, 3%-20%) and was not found on any non-T (CD3 À ) cells. The
78%-91%), and a small proportion were CD4 À CD8 þ (mean, 3%;
range, 1%-7%; Fig. 1A and D) . The remaining CD25 þ cells were 
Prognostic significance of TIL subsets
To investigate the prognostic significance of TIL subsets, a 187-case HGSC TMA was stained with antibodies to CD8, CD25, and FoxP3 ( Fig. 2A) . Because CD4 is also expressed by macrophages (6) , it is difficult to score CD4 þ TIL directly. Instead, we assumed that any CD25 þ and/or FoxP3 þ cell that did not express CD8 was a CD4 þ T cell, an assumption that was justified by the flow cytometry results shown in Fig. 1 . With this staining combination, we could directly visualize all CD8 þ TIL subsets, as well as the Fig. 1D and E) . We stained an adjacent section of the TMA for cytokeratin to unequivocally identify tumor epithelium versus stroma; for all subsequent analyses, we focused on intraepithelial TIL, as these have the greatest prognostic significance (2) . A large proportion of cases (74%) scored positive for CD8 þ TIL (Fig. 2B) , and consistent with the flow cytometry data, only a small number of CD8 þ TIL expressed CD25 and/or FoxP3 (data not shown). Over 90% of cases with CD8 þ TIL also had CD4 þ TIL of cases, respectively (Fig. 2B) . Thus, the different subsets of CD4 þ TIL were usually found together, although there were exceptions. All subsets of CD4 þ TIL showed a strong association with MHC class II expression by tumor cells (determined in a previous study of this cohort; ref. 7; P < 0.01 for all subsets).
As expected, CD8 þ TIL were strongly associated with diseasespecific survival (HR, 0.33; P < 0.0001; not shown) and progression-free survival (HR, 0.38; P < 0.0001; Fig. 3A) . The strong prognostic effect of CD8 þ TIL can confound the analysis of closely associated TIL subsets, such as Tregs (30) . Therefore, to determine the prognostic significance of CD4 þ TIL subsets, we restricted our analysis to cases that were positive for CD8 þ TIL. As expected, cases with a higher than median ratio of Tregs to CD8 þ TIL trended toward decreased survival (HR, 1.55; P ¼ 0.09; Fig.  3B ). In contrast, a higher than median ratio of CD25 Fig. 3E and F) . Thus, the CD25 Fig. S2B ). Similar to Tregs, CD25 þ FoxP3 À TIL expressed low levels of CD127 and moderate levels of GITR ( Supplementary Fig. S2C ). However, they expressed lower levels of CTLA-4 and OX40 than did Tregs and were negative for Helios (Fig. 4B ). These data suggested that CD25 Fig. S3B ) and failed to produce any of the hallmark Th1 cytokines IFNg, TNFa, or IL2 after in vitro stimulation with PMA and ionomycin (Fig. 4C) .
Indeed, Th1 cytokines were only produced by the CD25 À FoxP3 À subset (Fig. 4C) . None of the CD4 þ TIL subsets produced IL4 or IL17A ( Supplementary Fig. S2D ), and the expression of transcription factors GATA-3 (Th2) and RORgt (Th17) was restricted to minor subsets of CD4 þ CD25
À
FoxP3
À cells (Supplementary Fig.   S3D and S3F, and data not shown). All four CD4 þ TIL subsets expressed CXCR3 ( Supplementary Fig. S3C ), which is typical of T cells in inflammatory environments. Given that CD25 Fig. S2E ). Furthermore, CD25 þ FoxP3 À TIL did not express CXCR5, a marker of T follicular helper cells ( Supplementary  Fig. S2F ).
On the basis of their lack of discernible functional attributes, we hypothesized that CD25 þ FoxP3 À TIL might be in a suppressed or exhausted state. In accord with this, we found that CD25 þ FoxP3 À T cells expressed very high levels of the exhaustion marker PD-1 (Fig. 4D) . Indeed, the level of PD-1 expressed by CD25 þ FoxP3
À TIL was on average 3.1-fold higher than that by Tregs, and 6.6-fold higher than that by CD25 S2G ) and TIM-3, the latter being found on cells with the highest PD-1 levels (Fig. 4D) . Thus, despite being prognostically favorable, CD25 þ FoxP3 À TIL exhibited an exhausted phenotype based on the expression of these markers and deficient cytokine production. 
þ TIL. F, cases were stratified into two groups: above median CD25 þ FoxP3:CD8 þ ratio and below median CD25
In each plot, log-rank tests were used to determine P values, and HRs are shown for each analysis. For plots B to F, analyses were restricted to cases that were positive for CD8 þ TIL.
Discussion
Using multiparameter flow cytometry and IHC, we have shown that CD25 and FoxP3 delineate four subsets of CD4 þ TIL with distinct functional and prognostic attributes. Consistent with prior reports (8, (14) (15) (16) , CD25 þ FoxP3 þ Tregs constituted a substantial proportion of CD4 þ TIL, expressed canonical Treg markers (Helios, CTLA-4, and OX40), and showed a trend toward decreased patient survival. CD25 À FoxP3 À T cells constituted the largest subset of CD4 þ TIL and were the sole source of Th1 cytokines; however, despite their abundance and functional competence, these cells conferred no apparent prognostic benefit. Instead, the CD25 þ FoxP3 À subset showed a strong association with patient survival, despite expressing very high levels of PD-1 and failing to produce cytokines. This paradoxical relationship between functional status and prognosis might be explained by the fact that PD-1 is a marker of tumor-reactive TIL (34, 35) . Thus, the exhausted state of CD25 
FoxP3
À TIL play an inhibitory role in tumor immunity. However, this interpretation could potentially reflect a confounding effect of CD8 þ TIL. Specifically, cases exhibiting a low ratio of CD8 þ to CD25 þ FoxP3 À TIL were undoubtedly enriched for tumors with few or no CD8 þ TIL, which itself is a poor prognostic factor (2).
We attempted to correct for this effect by restricting our survival analysis to cases that were positive for CD8 þ TIL, thereby allowing us to assess any additional prognostic effects contributed by the different CD4 þ TIL subsets. The validity of this approach was supported by our finding, with few exceptions, that CD25 þ FoxP3 À TIL were found only in cases with CD8 þ TIL (Fig. 2B ).
With this correction, a strong positive prognostic effect of CD25 
À TIL have negligible (or possibly even negative) prognostic significance and that CD25 þ FoxP3 À TIL make a unique positive contribution to tumor immunity. At first glance, the above findings may appear inconsistent with prior studies reporting that TIL with Th1, Th17, or other cytokine patterns are prognostically favorable in ovarian (40) and other cancers (1) . However, many of these prior studies were based on the analysis of bulk tumor samples for expression of Th1-associated genes, such as IFNg, TNFa, T-bet, IRF-1, and STAT4 (10, 40 
À TIL, as the mechanisms of transcriptional regulation of the CD25 gene are relatively well characterized. The CD25 promoter has both positive and negative regulatory elements, which bind multiple factors, including NFAT, NF-kB, STAT5, and SMAD3/4 (44) . Transient CD25 expression is induced on virtually all T cells by activation of the T-cell receptor (TCR) and the downstream NFAT and NF-kB pathways (44) . CD25 can also be induced by a variety of cytokines, including IL1, IL2, IL7, IL12, IL15, TNFa, and TGFb (44) . In particular, IL2 induces CD25 expression via STAT5 (44) and in combination with extensive antigen stimulation induces expression of Blimp-1, which also upregulates CD25 expression (18) . Finally, CD25 is expressed at high, constitutive levels by Tregs through a combination of TCR signaling, IL2-induced STAT5 activation, and constitutive expression of FoxP3 (18) . In the case of CD25 
À cells is that they somehow maintain CD25 expression despite high levels of PD-1, which normally blunts TCR signaling through SHP-2-mediated dephosphorylation of ZAP70 (46) . This suggests that CD25 might be relatively insensitive to PD-1-mediated inhibition, as described for other gene products (47) . The findings reported here have implications for the development of effective immunotherapies for HGSC and related cancers. First, our data indicate that strategies to deplete Tregs by targeting CD25 might have the detrimental effect of also eliminating CD25 þ
À T cells. Indeed, in renal transplantation and autoimmunity, the net effect of anti-CD25 antibody therapy is immune suppression not activation (22) . Second, our findings might help to explain the positive clinical effects of IL2 in ovarian cancer, where a 25% response rate was achieved with intraperitoneal administration of IL2 as a monotherapy (26) . Third, our data have implications for checkpoint blockade strategies. Because many CD25 þ FoxP3 À TIL express high levels of CTLA-4 ( Fig. 4B) , treatment with antibodies to CTLA-4 might inadvertently deplete this TIL subset (48) . On the other hand, our data support further investigation of PD-1 blockade in HGSC, given that CD25 þ FoxP3 À TIL expressed the highest levels of PD-1 compared with all other CD4 þ TIL subsets (Fig.   4D ). That said, our data suggest that PD-1 might not be the only inhibitory mechanism affecting CD25 þ FoxP3 À TIL, because the stimulatory agents we used (PMA and ionomycin) are expected to bypass PD-1/SHP-2-mediated inhibition, yet failed to induce cytokine production by these cells (Fig. 4C) . Finally, our data reveal OX40 as a promising target for immune modulation, because this molecule was highly expressed by Tregs but not the other three CD4 þ TIL subsets (Fig. 4B ). Antibodies to OX40 can directly stimulate effector T cells (39, 49) , and they can also enhance antitumor immunity by depleting OX40 þ Tregs (50) . In summary, our study highlights the IL2, PD-1, and OX40 pathways as potential immunotherapeutic targets to differentially enhance the positive effects of CD25 þ FoxP3 À TIL over the inhibitory effects of Tregs.
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